--- title: FDA Panel Votes in Favor of "Female Viagra" description: Whether flibanserin receives official approval remains to be seen canonical: https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/ author: Alexandra Sifferlin article:opinion: false article:content_tier: free article:published_time: 2015-06-04T21:49:46.000Z article:modified_time: 2026-10-01T09:08:18.312Z article:section: Health og:title: FDA Panel Votes in Favor of 'Female Viagra' og:description: Whether flibanserin receives official approval remains to be seen og:url: https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt869816c570788ac0/6988526bf887dcc4a6e90b5e/flibanserin.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 og:image:width: 2560 og:image:height: 1440 og:image:alt: A tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters. og:type: article twitter:card: summary_large_image twitter:title: FDA Panel Votes in Favor of 'Female Viagra' twitter:description: Whether flibanserin receives official approval remains to be seen twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt869816c570788ac0/6988526bf887dcc4a6e90b5e/flibanserin.jpg?branch=production&width=1200&quality=75&auto=webp&crop=16:9 ---  # FDA Panel Votes in Favor of 'Female Viagra' > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=19602134-8f66-43bf-9604-b9ca353b61af&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=19602134-8f66-43bf-9604-b9ca353b61af&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=19602134-8f66-43bf-9604-b9ca353b61af&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=19602134-8f66-43bf-9604-b9ca353b61af&cr=time-nl-network-2026q3-v1) ## Video: Know Right Now: FDA To Discuss 'Women's Viagra' [Watch (HLS stream): Know Right Now: FDA To Discuss 'Women's Viagra'](https://cdn.jwplayer.com/manifests/qC7XnlGd.m3u8) (1:01)  _Published 2015-06-01. The FDA is discussing this week the approval of flibanserin, a drug that treats low libido in women_ by [Alexandra Sifferlin](https://time.com/author/alexandra-sifferlin/) ## Alexandra Sifferlin Jun 4, 2015 9:49 PM UTC by [Alexandra Sifferlin](https://time.com/author/alexandra-sifferlin/) ## Alexandra Sifferlin Jun 4, 2015 9:49 PM UTC An FDA advisory panel on Thursday [voted](http://www.nytimes.com/2015/06/05/business/panel-backs-a-drug-to-increase-womens-sex-drive.html) 18 to 6 in support of approving a drug that would help to increase libido in women who lack sexual desire. The panel said the drug, flibanserin, should be approved if measures are taken to deal with side effects, the New York _Times_ reports. The FDA will use the panel’s decision as a recommendation. Flibanserin, which is owned by Sprout Pharmaceuticals, has been rejected by the FDA in the past. The drug is meant for women with low sexual desire, specifically Hypoactive Sexual Desire Disorder (HSDD), and many advocates for the drug’s approval have argued that women don’t have any drugs to treat sexual dysfunction while men have several. The FDA has had previous concerns about the drug’s side effects, which include nausea, sleepiness and, in rare cases, low blood pressure and fainting. The drug is thought to work by targeting neurotransmitters in the brain involved with sexual desire. It temporarily lowers serotonin levels and raises the levels of dopamine and norepinephrine. Some have argued that its benefit is slight. “I think it would be nice if a drug like this could work, having better sex is important to my patients,” Dr. Mary Jane Minkin, a clinical professor of obstetrics, gynecology and reproductive services at Yale School of Medicine, [told TIME on Monday](http://time.com/3903222/women-viagra-fda-drug/?xid=tcoshare). “The earlier results showed it definitely increased desire, but the benefit was not overwhelming enough.” But those who lack sexual desire said it’s worth it. Thursday’s meeting included about two hours of public testimony. Katherine Campbell, a married mother from Indiana who has not yet tried out the drug, said “critics say the improvement might only be modest, but oh what I would give for even a modest improvement.” Whether the drug will receive approval is yet to be seen. [_Read Next: Will the New ‘Women’s Viagra’ Finally Get FDA Approval?_](http://time.com/3903222/women-viagra-fda-drug/?xid=tcoshare) ## Transcript [ MUSIC ] ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/"},"headline":"FDA Panel Votes in Favor of 'Female Viagra'","datePublished":"2015-06-04T21:49:46.000Z","dateModified":"2026-10-01T09:08:18.312Z","description":"Whether flibanserin receives official approval remains to be seen","url":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/","keywords":["medicine","Sex","FDA","Viagra"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt869816c570788ac0/6988526bf887dcc4a6e90b5e/flibanserin.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alexandra Sifferlin","jobTitle":null,"url":"https://time.com/author/alexandra-sifferlin/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt869816c570788ac0/6988526bf887dcc4a6e90b5e/flibanserin.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"A tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters.","caption":"A tablet of flibanserin sits on a brochure for Sprout Pharmaceuticals in the company's Raleigh, N.C., headquarters.","creditText":"Allen Breed—AP","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"/tag/medicine/","name":"medicine"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/","name":"FDA Panel Votes in Favor of 'Female Viagra'"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Know Right Now: FDA To Discuss 'Women's Viagra'","description":"The FDA is discussing this week the approval of flibanserin, a drug that treats low libido in women","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/qC7XnlGd/poster.jpg?width=720","uploadDate":"2015-06-01T19:37:04.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/qC7XnlGd.m3u8","embedUrl":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/","duration":"PT1M1S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/3910040/fad-advisory-panel-female-viagra-flibanserin/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}] ```